滨州医学院学报
濱州醫學院學報
빈주의학원학보
JOURNAL OF BINZHOU MEDICAL COLLEGE
2014年
1期
5-8
,共4页
韩艳春%刘鲁英%王霞%张骞
韓豔春%劉魯英%王霞%張鶱
한염춘%류로영%왕하%장건
乳腺癌%多药耐药%激素受体
乳腺癌%多藥耐藥%激素受體
유선암%다약내약%격소수체
Breast carcinoma%Multidrug resistance%Hormone receptor
目的:探讨多药耐药基因产物谷胱甘肽转移酶π( GST-π)、肺耐药相关蛋白( LRP)和DNA拓扑异构酶Ⅱ( TopoⅡ)和雌激素受体( ER)、孕激素受体( PR)在乳腺浸润性导管癌组织中的表达及临床意义,并分析多药耐药基因产物与雌、孕激素受体之间是否有关联。方法应用免疫组织化学SP二步法检测194例乳腺浸润性导管癌组织中GST-π、LRP、TopoⅡ、ER、PR的表达,且结合乳腺癌临床病理因素进行分析。结果194例乳腺浸润性导管癌组织中GST-π、LRP、TopoⅡ表达的阳性率分别为62.4%、81.4%、51.5%。 LRP和TopoⅡ在伴有淋巴结转移的乳腺浸润性导管癌患者中的表达高于无淋巴结转移者( P<0.05),而与患者年龄、肿块长径、组织学分级、TNM分期等临床病理因素之间无相关性(P>0.05);LRP和TopoⅡ的表达与ER、PR的表达均无明显相关性( P>0.05)。 GST-π的表达与ER、PR的表达呈负相关( P<0.05),而与其它临床病理因素之间未见相关性( P>0.05)。 LRP、GST-π、TopoⅡ两两之间无相关性( P>0.05)。结论 GST-π、LRP、TopoⅡ与乳腺浸润性导管癌的多药耐药有关,且LRP和TopoⅡ与乳腺癌的转移有一定关系,GST-π与ER、PR负性相关。联合检测可为乳腺癌的临床化疗药物选择及评估预后提供依据。
目的:探討多藥耐藥基因產物穀胱甘肽轉移酶π( GST-π)、肺耐藥相關蛋白( LRP)和DNA拓撲異構酶Ⅱ( TopoⅡ)和雌激素受體( ER)、孕激素受體( PR)在乳腺浸潤性導管癌組織中的錶達及臨床意義,併分析多藥耐藥基因產物與雌、孕激素受體之間是否有關聯。方法應用免疫組織化學SP二步法檢測194例乳腺浸潤性導管癌組織中GST-π、LRP、TopoⅡ、ER、PR的錶達,且結閤乳腺癌臨床病理因素進行分析。結果194例乳腺浸潤性導管癌組織中GST-π、LRP、TopoⅡ錶達的暘性率分彆為62.4%、81.4%、51.5%。 LRP和TopoⅡ在伴有淋巴結轉移的乳腺浸潤性導管癌患者中的錶達高于無淋巴結轉移者( P<0.05),而與患者年齡、腫塊長徑、組織學分級、TNM分期等臨床病理因素之間無相關性(P>0.05);LRP和TopoⅡ的錶達與ER、PR的錶達均無明顯相關性( P>0.05)。 GST-π的錶達與ER、PR的錶達呈負相關( P<0.05),而與其它臨床病理因素之間未見相關性( P>0.05)。 LRP、GST-π、TopoⅡ兩兩之間無相關性( P>0.05)。結論 GST-π、LRP、TopoⅡ與乳腺浸潤性導管癌的多藥耐藥有關,且LRP和TopoⅡ與乳腺癌的轉移有一定關繫,GST-π與ER、PR負性相關。聯閤檢測可為乳腺癌的臨床化療藥物選擇及評估預後提供依據。
목적:탐토다약내약기인산물곡광감태전이매π( GST-π)、폐내약상관단백( LRP)화DNA탁복이구매Ⅱ( TopoⅡ)화자격소수체( ER)、잉격소수체( PR)재유선침윤성도관암조직중적표체급림상의의,병분석다약내약기인산물여자、잉격소수체지간시부유관련。방법응용면역조직화학SP이보법검측194례유선침윤성도관암조직중GST-π、LRP、TopoⅡ、ER、PR적표체,차결합유선암림상병리인소진행분석。결과194례유선침윤성도관암조직중GST-π、LRP、TopoⅡ표체적양성솔분별위62.4%、81.4%、51.5%。 LRP화TopoⅡ재반유림파결전이적유선침윤성도관암환자중적표체고우무림파결전이자( P<0.05),이여환자년령、종괴장경、조직학분급、TNM분기등림상병리인소지간무상관성(P>0.05);LRP화TopoⅡ적표체여ER、PR적표체균무명현상관성( P>0.05)。 GST-π적표체여ER、PR적표체정부상관( P<0.05),이여기타림상병리인소지간미견상관성( P>0.05)。 LRP、GST-π、TopoⅡ량량지간무상관성( P>0.05)。결론 GST-π、LRP、TopoⅡ여유선침윤성도관암적다약내약유관,차LRP화TopoⅡ여유선암적전이유일정관계,GST-π여ER、PR부성상관。연합검측가위유선암적림상화료약물선택급평고예후제공의거。
Objective To explore the expression and clinical significance of multidrug resistance gene products glutathione -S-trans-ferase-π(GST-π) , lung resistance protein (LRP),topoisomeraseⅡ(TopoⅡ), estrogen receptor(ER) and progesterone receptor ( PR) in breast invasive ductal carcinoma tissues ,and analyze whether there is a connection between multi-drug resistant gene product and hormone recepor .Methods Expression of LRP ,GST-π,TopoⅡ,ER and PR was examined in the tissue sections from 194 cases of human breast invasive ductal carcinoma using streptoavidin-biotin-peroxidase immunohistochemistry method ,and analyse their correla-tion to clinicopathological characteristics of breast carcinoma .Results Positive rate of GST-π,LRP and TopoⅡ expression in breast invasive ductal carcinoma tissues was 62.4%, 81.4%and 51.5%, respectively .Expression of LRP and TopoⅡ was higher in lymph node metastasis group than that in non-lymph node metastasis group (P<0.05),and it was not related to age of patients , tumor longest diameter, tumor grade,TNM stage,ER and PR.Expression of GST-πwas negtively related to ER and PR (P<0.05),and it was not related to other clinico pathological characteristics .There is not related to between LRP ,GST-πand TopoⅡ(P>0.05).Conclusions Expression of LRP ,GST-πand TopoⅡis related to multidrug resistance of breast invasive ductal carcinoma .LRP and TopoⅡis re-lated to the invasion and metastasis of breast cancer .GST-πwas negtively related to ER and PR .Choosing the chemotherapeutics and assessing prognosis are on the basis of the joint detection of LRP ,GST-πand TopoⅡ.